<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T12:35:36Z</responseDate>
  <request identifier="oai:figshare.com:article/33957061" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33957061</identifier>
        <datestamp>2026-09-21T17:40:09Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_45</setSpec>
        <setSpec>category_734</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Scenario analysis: total costs, cost per screening, and cost per TB case detected by screening approach and country (TB-only screening).&lt;/p&gt;</dc:title>
          <dc:creator>Harsh Vivek Harkare (15271402)</dc:creator>
          <dc:creator>Anna Verjans (23447728)</dc:creator>
          <dc:creator>Phillip Joseph (7705154)</dc:creator>
          <dc:creator>Mashaete Kamele (675523)</dc:creator>
          <dc:creator>Shriya Misra (13812989)</dc:creator>
          <dc:creator>Mamatlakeng Keitseng (25084569)</dc:creator>
          <dc:creator>Mojabeng Mabeleng (25084572)</dc:creator>
          <dc:creator>Thandanani Madonsela (17696684)</dc:creator>
          <dc:creator>Alastair van Heerden (512947)</dc:creator>
          <dc:creator>Johanna Kurscheid (802752)</dc:creator>
          <dc:creator>Bart K.M. Jacobs (25084575)</dc:creator>
          <dc:creator>Aita Signorell (13730084)</dc:creator>
          <dc:creator>Fiona Vanobberghen (2735740)</dc:creator>
          <dc:creator>Klaus Reither (259897)</dc:creator>
          <dc:creator>Irene Ayakaka (121859)</dc:creator>
          <dc:creator>Shannon Bosman (15460919)</dc:creator>
          <dc:creator>Fabrizio Tediosi (247282)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Sociology</dc:subject>
          <dc:subject>Biological Sciences not elsewhere classified</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>observed prevalence would</dc:subject>
          <dc:subject>averted confirmatory tests</dc:subject>
          <dc:subject>948 – 9</dc:subject>
          <dc:subject>67 – 72</dc:subject>
          <dc:subject>023 participants screened</dc:subject>
          <dc:subject>000 participants ).</dc:subject>
          <dc:subject>dominant cost driver</dc:subject>
          <dc:subject>comparative cost analysis</dc:subject>
          <dc:subject>september 2024 ),</dc:subject>
          <dc:subject>rays alone (&lt;</dc:subject>
          <dc:subject>div &gt;&lt; p</dc:subject>
          <dc:subject>expanded screening volume</dc:subject>
          <dc:subject>crp approach &lt;/</dc:subject>
          <dc:subject>ui ]: 4</dc:subject>
          <dc:subject>requires prospective evaluation</dc:subject>
          <dc:subject>recurrent costs accounted</dc:subject>
          <dc:subject>294 – 6</dc:subject>
          <dc:subject>cad4tbv7 approach &lt;/</dc:subject>
          <dc:subject>reactive protein testing</dc:subject>
          <dc:subject>alone versus cad</dc:subject>
          <dc:subject>lesotho &lt;/ p</dc:subject>
          <dc:subject>tb screening strategies</dc:subject>
          <dc:subject>based tuberculosis screening</dc:subject>
          <dc:subject>based approach</dc:subject>
          <dc:subject>reactive protein</dc:subject>
          <dc:subject>cad4tbv7 &lt;/</dc:subject>
          <dc:subject>additional cost</dc:subject>
          <dc:subject>crp testing</dc:subject>
          <dc:subject>september 2022</dc:subject>
          <dc:subject>testing within</dc:subject>
          <dc:subject>yet evidence</dc:subject>
          <dc:subject>whereas scaling</dc:subject>
          <dc:subject>vehicle costs</dc:subject>
          <dc:subject>usd 7</dc:subject>
          <dc:subject>total costs</dc:subject>
          <dc:subject>south africa</dc:subject>
          <dc:subject>programmatic perspective</dc:subject>
          <dc:subject>participant numbers</dc:subject>
          <dc:subject>paired screen</dc:subject>
          <dc:subject>nested within</dc:subject>
          <dc:subject>local epidemiological</dc:subject>
          <dc:subject>implementation costs</dc:subject>
          <dc:description>&lt;p&gt;Scenario analysis: total costs, cost per screening, and cost per TB case detected by screening approach and country (TB-only screening).&lt;/p&gt;</dc:description>
          <dc:date>2026-09-21T17:40:03Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pgph.0007341.t002</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Scenario_analysis_total_costs_cost_per_screening_and_cost_per_TB_case_detected_by_screening_approach_and_country_TB-only_screening_p_/33957061</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
